Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 80.32M | 84.61M | 73.48M | 65.05M | 85.49M | 78.65M |
Gross Profit | 25.26M | 26.82M | 18.21M | 13.35M | 31.66M | 20.11M |
EBITDA | -80.80M | -70.30M | -96.81M | -104.64M | -59.01M | -34.05M |
Net Income | -91.32M | -81.28M | -108.30M | -113.31M | -65.23M | -41.28M |
Balance Sheet | ||||||
Total Assets | 258.68M | 270.27M | 225.10M | 292.70M | 396.53M | 244.84M |
Cash, Cash Equivalents and Short-Term Investments | 173.23M | 185.01M | 114.18M | 167.66M | 287.06M | 203.29M |
Total Debt | 42.44M | 44.25M | 48.96M | 48.65M | 52.80M | 10.99M |
Total Liabilities | 67.85M | 67.31M | 95.66M | 74.56M | 86.23M | 49.90M |
Stockholders Equity | 190.83M | 202.96M | 129.44M | 218.14M | 310.30M | 194.94M |
Cash Flow | ||||||
Free Cash Flow | -49.18M | -46.75M | -67.17M | -120.13M | -81.91M | -45.90M |
Operating Cash Flow | -44.89M | -45.15M | -56.26M | -70.23M | -70.83M | -42.65M |
Investing Cash Flow | -81.28M | -35.07M | 13.10M | 52.54M | -60.07M | -65.14M |
Financing Cash Flow | 131.79M | 114.67M | 11.03M | 1.37M | 169.70M | 121.27M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | 691.46M | -13.54 | -4.57% | ― | 4.31% | 69.57% | |
59 Neutral | 658.78M | -63.85 | -2.08% | ― | 20.40% | -165.41% | |
58 Neutral | 794.68M | 14.62 | 15.79% | ― | 14.72% | ― | |
52 Neutral | $535.61M | ― | -60.26% | ― | 0.36% | 22.13% | |
52 Neutral | 716.44M | -1.80 | -101.83% | ― | 3.83% | -137.31% | |
48 Neutral | 496.59M | -4.06 | -28.38% | ― | 13.17% | 64.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 19, 2025, Personalis, Inc. announced a new task order under its contract with the U.S. Department of Veterans Affairs for the Million Veteran Program, effective September 30, 2025, valued at up to $13.5 million. This order increases the cumulative value of task orders received by Personalis under its contracts with the VA MVP to approximately $225.0 million, highlighting the company’s significant role in this large-scale genomic research initiative.
On July 8, 2025, Personalis, Inc. and Tempus AI, Inc. amended their existing agreement to include colorectal cancer as a new indication for the NeXT Personal® test, alongside breast cancer, lung cancer, and immuno-oncology monitoring. The amendment extends the exclusivity period for marketing the test and modifies certain standstill restrictions, potentially strengthening Personalis’ market position in cancer diagnostics.